Is 10X Genomics Stock a Good Investment?
10X Genomics Investment Advice | TXG |
- Examine 10X Genomics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research 10X Genomics' leadership team and their track record. Good management can help 10X Genomics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact 10X Genomics' business and its evolving consumer preferences.
- Compare 10X Genomics' performance and market position to its competitors. Analyze how 10X Genomics is positioned in terms of product offerings, innovation, and market share.
- Check if 10X Genomics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about 10X Genomics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in 10X Genomics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if 10X Genomics is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Solid | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine 10X Genomics Stock
Researching 10X Genomics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The book value of 10X Genomics was at this time reported as 5.74. The company has Price/Earnings To Growth (PEG) ratio of 0.13. 10X Genomics recorded a loss per share of 1.3. The entity had not issued any dividends in recent years. The firm had 1:2 split on the 17th of July 2006.
To determine if 10X Genomics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding 10X Genomics' research are outlined below:
| 10X Genomics appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 610.78 M. Reported Net Loss for the year was (182.63 M) with profit before taxes, overhead, and interest of 427.01 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: 10x Genomics and ASTAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery |
10X Genomics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in 10X Genomics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to 10X Genomics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact 10X Genomics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises 10X Genomics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-13 | 2024-12-31 | -0.1067 | -0.1356 | -0.0289 | 27 | ||
2024-10-29 | 2024-09-30 | -0.34 | -0.3 | 0.04 | 11 | ||
2020-02-18 | 2019-12-31 | -0.11 | -0.07 | 0.04 | 36 | ||
2024-02-15 | 2023-12-31 | -0.36 | -0.41 | -0.05 | 13 | ||
2021-11-03 | 2021-09-30 | -0.2 | -0.15 | 0.05 | 25 | ||
2019-09-11 | 2019-06-30 | -0.11 | -0.16 | -0.05 | 45 | ||
2023-05-03 | 2023-03-31 | -0.37 | -0.44 | -0.07 | 18 | ||
2022-05-04 | 2022-03-31 | -0.31 | -0.38 | -0.07 | 22 |
Know 10X Genomics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 10X Genomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 10X Genomics backward and forwards among themselves. 10X Genomics' institutional investor refers to the entity that pools money to purchase 10X Genomics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ra Capital Management, Llc | 2025-03-31 | 1.9 M | Geode Capital Management, Llc | 2025-03-31 | 1.9 M | State Street Corp | 2025-03-31 | 1.8 M | Two Sigma Advisers, Llc | 2025-03-31 | 1.7 M | Assenagon Asset Management Sa | 2025-03-31 | 1.7 M | Voloridge Investment Management, Llc | 2025-03-31 | 1.6 M | Deerfield Management Co | 2025-03-31 | 1.5 M | Capital World Investors | 2025-03-31 | 1.5 M | Two Sigma Investments Llc | 2025-03-31 | 1.4 M | Ark Investment Management Llc | 2025-03-31 | 12.8 M | Vanguard Group Inc | 2025-03-31 | 11.1 M |
10X Genomics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 1.5 B.Market Cap |
|
10X Genomics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.24) | (0.26) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.26) | (0.27) |
Determining 10X Genomics' profitability involves analyzing its financial statements and using various financial metrics to determine if 10X Genomics is a good buy. For example, gross profit margin measures 10X Genomics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of 10X Genomics' profitability and make more informed investment decisions.
10X Genomics' Earnings Breakdown by Geography
Evaluate 10X Genomics' management efficiency
10X Genomics has Return on Asset of (0.1243) % which means that on every $100 spent on assets, it lost $0.1243. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2203) %, meaning that it generated no profit with money invested by stockholders. 10X Genomics' management efficiency ratios could be used to measure how well 10X Genomics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.21. The current Return On Capital Employed is estimated to decrease to -0.26. At this time, 10X Genomics' Intangibles To Total Assets are most likely to slightly decrease in the upcoming years. The 10X Genomics' current Debt To Assets is estimated to increase to 0.12, while Non Current Assets Total are projected to decrease to roughly 230.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.90 | 6.19 | |
| Tangible Book Value Per Share | 5.73 | 6.01 | |
| Enterprise Value Over EBITDA | (10.96) | (11.51) | |
| Price Book Value Ratio | 2.44 | 2.31 | |
| Enterprise Value Multiple | (10.96) | (11.51) | |
| Price Fair Value | 2.44 | 2.31 | |
| Enterprise Value | 5.7 B | 5 B |
The management strategies employed by 10X Genomics' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 1.981 |
Basic technical analysis of 10X Stock
As of the 20th of July, 10X Genomics shows the mean deviation of 2.88, and Coefficient Of Variation of 565.28. Compared to fundamental indicators, the technical analysis model gives you tools to check timely technical drivers of 10X Genomics, as well as the relationship between them. Please confirm 10X Genomics standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if 10X Genomics is priced more or less accurately, providing market reflects its regular price of 12.15 per share. Given that 10X Genomics has jensen alpha of 0.3975, we suggest you to validate 10X Genomics's prevailing market performance to make sure the company can sustain itself sooner or later.10X Genomics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 10X Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on 10X Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 10X Genomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
10X Genomics' Outstanding Corporate Bonds
10X Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. 10X Genomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most 10X bonds can be classified according to their maturity, which is the date when 10X Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| US88023UAJ07 Corp BondUS88023UAJ07 | View | |
| US88023UAH41 Corp BondUS88023UAH41 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand 10X Genomics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing 10X Genomics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1727 | |||
| Market Risk Adjusted Performance | 0.3559 | |||
| Mean Deviation | 2.88 | |||
| Semi Deviation | 3.39 | |||
| Downside Deviation | 3.82 | |||
| Coefficient Of Variation | 565.28 | |||
| Standard Deviation | 3.67 | |||
| Variance | 13.47 | |||
| Information Ratio | 0.1385 | |||
| Jensen Alpha | 0.3975 | |||
| Total Risk Alpha | 0.1253 | |||
| Sortino Ratio | 0.1332 | |||
| Treynor Ratio | 0.3459 | |||
| Maximum Drawdown | 16.59 | |||
| Value At Risk | (5.92) | |||
| Potential Upside | 7.07 | |||
| Downside Variance | 14.57 | |||
| Semi Variance | 11.49 | |||
| Expected Short fall | (3.13) | |||
| Skewness | (0.30) | |||
| Kurtosis | 0.0748 |
| Risk Adjusted Performance | 0.1727 | |||
| Market Risk Adjusted Performance | 0.3559 | |||
| Mean Deviation | 2.88 | |||
| Semi Deviation | 3.39 | |||
| Downside Deviation | 3.82 | |||
| Coefficient Of Variation | 565.28 | |||
| Standard Deviation | 3.67 | |||
| Variance | 13.47 | |||
| Information Ratio | 0.1385 | |||
| Jensen Alpha | 0.3975 | |||
| Total Risk Alpha | 0.1253 | |||
| Sortino Ratio | 0.1332 | |||
| Treynor Ratio | 0.3459 | |||
| Maximum Drawdown | 16.59 | |||
| Value At Risk | (5.92) | |||
| Potential Upside | 7.07 | |||
| Downside Variance | 14.57 | |||
| Semi Variance | 11.49 | |||
| Expected Short fall | (3.13) | |||
| Skewness | (0.30) | |||
| Kurtosis | 0.0748 |
Consider 10X Genomics' intraday indicators
10X Genomics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of 10X Genomics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
10X Genomics Corporate Filings
| 16th of July 2025 Other Reports | ViewVerify | |
F4 | 11th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 5th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 9th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
10X Stock media impact
There is far too much social signal, news, headlines, and media speculation about 10X Genomics that are available to investors today. This information is accessible both publicly - through 10X Genomics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of 10X-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of 10X Genomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of 10X Genomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to 10X Genomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive 10X Genomics alpha.
10X Genomics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards 10X Genomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
10X Genomics Historical Investor Sentiment
Investor biases related to 10X Genomics' public news can be used to forecast risks associated with an investment in 10X. The trend in average sentiment can be used to explain how an investor holding 10X can time the market purely based on public headlines and social activities around 10X Genomics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
10X Genomics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for 10X Genomics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average 10X Genomics news discussions. The higher the estimate score, the more favorable the investor's outlook on 10X Genomics.
10X Genomics Corporate Management
| James Wilbur | Chief Officer | Profile | |
| Mennah Moustafa | Chief Officer | Profile | |
| Ruth Backer | Chief Officer | Profile | |
| Florian Baumgartner | Senior Manager | Profile | |
| Jonathan Schimmel | VP Operations | Profile | |
| Jim Goodrich | Chief Operations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.30) | Revenue Per Share | Quarterly Revenue Growth 0.098 | Return On Assets | Return On Equity |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between 10X Genomics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.